Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.53 |
| ▸ | ESR1 | P03372 | 7/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656067 | 0.90 | OPRK1 (0.51) | OPRK1ESR2ESR1TTRDRD2 | |
| SCHEMBL4362691 | 0.90 | OPRK1 (0.56) | OPRK1ESR2ESR1DRD2DRD3 | |
| SCHEMBL29683543 | 0.90 | OPRK1 (0.56) | OPRK1ESR2ESR1DRD2DRD3 | |
| SCHEMBL13873900 | 0.90 | OPRK1 (0.51) | OPRK1ESR2ESR1TTRDRD2 | |
| SCHEMBL21780916 | 0.90 | OPRK1 (0.56) | OPRK1ESR2ESR1DRD2DRD3 | |
| SCHEMBL5580620 | 0.88 | OPRK1 (0.57) | OPRK1ESR2ESR1TTRDRD2 | |
| SCHEMBL19428987 | 0.86 | CYP26A1 (0.52) | OPRK1ESR2ESR1DRD2DRD3 | |
| SCHEMBL31279833 | 0.84 | CA1 (0.51) | OPRK1ESR2ESR1TTRDRD2 | |
| SCHEMBL227769 | 0.77 | OPRK1 (0.57) | OPRK1ESR2ESR1DRD2DRD3 | |
| SCHEMBL14219186 | 0.76 | ALDH5A1 (0.41) | OPRK1ESR2ESR1TTRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406206-B1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | MSD OSS BV (NL) | 2013-01-30 | — | — | EP | disclosed |
| EP-2406206-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | MSD Oss B.V. (NL) | 2012-01-18 | — | — | EP | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
| WO-2010103095-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N.V. ORGANON (NL) | 2010-09-16 | — | — | WO | disclosed |
| US-7196081-B2 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | VHL, BRCA1, TPH2 | OPRK1 92/4885ESR2 20/4885ESR1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.